| P50 | author | Kim E Nichols | Q88215766 |
| | Sabrin Albeituni | Q57013080 |
| | Heather S Tillman | Q59116788 |
| | Jennifer Picarsic | Q61126191 |
| | Katherine C Verbist | Q63976361 |
| P2093 | author name string | Rachel Bassett | |
| | Paige E Tedrick | |
| P2860 | cites work | Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes | Q27011625 |
| | Fiji: an open-source platform for biological-image analysis | Q27860912 |
| | Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice | Q28594763 |
| | Thrombocytopenia in association with splenomegaly during granulocyte-colony-stimulating factor treatment in mice is not caused by hypersplenism and is resolved spontaneously | Q33373777 |
| | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 |
| | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 |
| | Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis | Q33429617 |
| | Aplastic anemia rescued by exhaustion of cytokine-secreting CD8+ T cells in persistent infection with lymphocytic choriomeningitis virus | Q33502619 |
| | HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. | Q34561113 |
| | Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis | Q34924532 |
| | Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. | Q35015661 |
| | Hemophagocytosis causes a consumptive anemia of inflammation | Q35213574 |
| | Targeting the Jak/STAT pathway for immunosuppression | Q35579377 |
| | Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 |
| | Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis | Q89777237 |
| | Immune function in mice lacking the perforin gene | Q35882128 |
| | Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice | Q36042041 |
| | ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice | Q36517280 |
| | The JAK-STAT signaling pathway: input and output integration | Q36740971 |
| | Myelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitis | Q37242355 |
| | TLR9-mediated inflammation drives a Ccr2-independent peripheral monocytosis through enhanced extramedullary monocytopoiesis | Q37305022 |
| | Chronic but not acute virus infection induces sustained expansion of myeloid suppressor cell numbers that inhibit viral-specific T cell immunity | Q37406565 |
| | Hemophagocytic syndromes--an update | Q38208981 |
| | The JAK-STAT pathway: impact on human disease and therapeutic intervention | Q38317993 |
| | Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report. | Q38611574 |
| | Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis | Q39705269 |
| | IFN-gamma-induced TNF-alpha expression is regulated by interferon regulatory factors 1 and 8 in mouse macrophages | Q39938350 |
| | Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. | Q40247636 |
| | Interferon-γ mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice | Q40252348 |
| | Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children | Q40299960 |
| | Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis | Q40490433 |
| | An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder | Q40536555 |
| | Attenuated viral hepatitis in Trem1-/- mice is associated with reduced inflammatory activity of neutrophils | Q40689296 |
| | A novel role for STAT1 in regulating murine erythropoiesis: deletion of STAT1 results in overall reduction of erythroid progenitors and alters their distribution | Q44948873 |
| | Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. | Q45930884 |
| | JAK inhibition as a therapeutic strategy for immune and inflammatory diseases | Q47439880 |
| | Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience. | Q48309807 |
| | Ruxolitinib as First-Line Treatment in Secondary Hemophagocytic Lymphohistiocytosis: A Second Experience. | Q50125132 |
| | IL-33 induces immunosuppressive neutrophils via a type 2 innate lymphoid cell/IL-13/STAT6 axis and protects the liver against injury in LCMV infection-induced viral hepatitis. | Q50199697 |
| | Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. | Q50503576 |
| | Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis. | Q51691055 |
| | Increased serum monocyte chemoattractant protein-1, macrophage inflammatory protein-1beta, and interleukin-8 concentrations in hemophagocytic lymphohistiocytosis. | Q51952551 |
| | Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. | Q53916622 |
| | Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses. | Q54117915 |
| | JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. | Q55548365 |
| | Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs | Q57164859 |
| | Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis | Q58912330 |
| | Nitric oxide regulates endotoxin-induced TNF-alpha production by human neutrophils | Q72332901 |
| | Involvement of interferon-gamma and macrophage colony-stimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults | Q72772336 |
| | Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis | Q73374152 |
| | Effects of TREM-1 activation in human neutrophils: activation of signaling pathways, recruitment into lipid rafts and association with TLR4 | Q79349810 |
| | Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis | Q84751886 |
| | Successful use of infliximab in macrophage activation syndrome with severe CNS involvement | Q85088572 |
| | Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11 | Q85474057 |
| P433 | issue | 2 | |
| P921 | main subject | hemophagocytic lymphohistiocytosis | Q1642170 |
| | ruxolitinib | Q7383611 |
| | murine model | Q122890741 |
| P304 | page(s) | 147-159 | |
| P577 | publication date | 2019-04-23 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis | |
| P478 | volume | 134 | |